ATTD – Lilly Insulin Centennial Award
We acknowledge the significance and value of ongoing innovation in diabetes.
In honor of the 100th anniversary of insulin, ATTD will award a prize supported by Eli Lilly to a practice/innovative way of managing diabetes.
Submit your nominee in the form below by 1 February 2023
- Today, 61 million people live with diabetes in Europe. The number of PwD is expected to rise to 69 million by 2045, which means that, by then, 1 in 10 Europeans could be living with diabetes(1).
- 75% of these costs are related to diabetes complications that are preventable with proper treatment(2). Out of the total diabetes costs in the Big EU 5 in 2012, the percentage spent on insulin and anti-diabetic medicines ranged between 6% and 11%(3).
- Every 6 seconds, a PwD dies because of a diabetes-related complication(4).
- Only 50% of PwD reach the appropriate blood sugar levels for the condition (HBA1C <7.0%).
Reasons for outcomes non improving are strong conservatism, clinical inertia and treat-to fail paradigm.
- According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus algorithm(5-6), 30–60% of people with type 2 diabetes would qualify for more effective treatment(7). However, in clinical reality, the percentage of PwD receiving more effective treatment remains very low, ranging between 1% and 10%(8).
- Inertia for HCP is the recurring failure to establish appropriate targets and escalate treatment to achieve treatment goals (9), but also the behaviour to not setting clear goals or insufficient focus on goal attainment (10,11), or inadequate time/personnel to teach injectable therapy(10,11).
We need to modernize diabetes care.